Weekly osimertinib dosing prevents EGFR mutant tumor cells destined to home mouse lungs

The recently conducted ADAURA trial concludes daily dosing of adjuvant osimertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI), improves disease-free survival with stage IB/II/IIIA EGFR -mutated non-small cell lung cancer patients in comparison to placebo. We have developed a preclinica...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Transl Oncol
Egile Nagusiak: Butle, Ashwin, Joshi, Asim, Noronha, Vanita, Prabhash, Kumar, Dutt, Amit
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Neoplasia Press 2021
Gaiak:
Spotlight
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC8236545/
https://ncbi.nlm.nih.gov/pubmed/33993094
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.tranon.2021.101111
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak